Sophie Raherison
University of Bordeaux
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sophie Raherison.
Antimicrobial Agents and Chemotherapy | 2002
Sabine Pereyre; P. Gonzalez; B. de Barbeyrac; A. Darnige; H. Renaudin; A. Charron; Sophie Raherison; C. Bébéar; Cécile Bébéar
ABSTRACT The mechanisms of intrinsic resistance of Mycoplasma hominis to 14- and 15-membered macrolides were investigated in comparison with those of M. pneumoniae, which is naturally susceptible to macrolides. Radiolabeled erythromycin was not accumulated by M. hominis PG21, but addition of an ABC transporter inhibitor increased the level of erythromycin uptake more than two times, suggesting the existence of an active efflux process. The affinity of [14C]erythromycin to ribosomes isolated from M. hominis was dramatically reduced relative to that to ribosomes isolated from M. pneumoniae. The nucleotide sequences of 23S rRNA of both ribosomal operons rrnA and rrnB and ribosomal proteins L4 and L22 of M. hominis were obtained. Compared to the sequence of M. pneumoniae, M. hominis harbored a G2057A transition in its 23S rRNA sequence, as did M. fermentans, another mycoplasma that is erythromycin resistant. An additional C2610U change was also found in the sequence of M. hominis. Moreover, two M. hominis clinical isolates with acquired resistance to 16-membered macrolides were examined for mutations in domain II and domain V of 23S rRNA and in ribosomal proteins L4 and L22. Compared to the sequence of reference strain PG21, one isolate harbored a A2059G transition and a C2611U transition in one of the two rrn operons, while the other one was mutated only at position 2059, also on the same operon. No mutation was found in the two ribosomal protein sequences. Overall, the present study is an exhaustive characterization of the intrinsic resistance of M. hominis to 14- and 15-membered macrolides and the first description of mycoplasma clinical isolates resistant to macrolide, lincosamide, and streptogramin antibiotics harboring a mutation at position 2611 in the 23S rRNA.
Antimicrobial Agents and Chemotherapy | 2005
Sophie Raherison; Patrice Gonzalez; H. Renaudin; A. Charron; C. Bébéar; Cécile Bébéar
ABSTRACT Two genes, md1 and md2, coding for multidrug resistance ATP-binding cassette transporters were identified in Mycoplasma hominis PG21. Expression of these two genes, quantified by quantitative competitive reverse transcription-PCR, was significantly increased in ethidium bromide-resistant strains of M. hominis compared to that in M. hominis PG21.
Journal of Medical Microbiology | 2011
Olivia Peuchant; Jean Philippe Duvert; M. Clerc; Sophie Raherison; C. Bébéar; Cécile Bébéar; Bertille de Barbeyrac
The objective of this study was to determine the effect of antibiotics on Chlamydia trachomatis viability by using a quantitative real-time PCR assay that measured DNA replication and mRNA transcription of the structural omp1 and omp2 genes, 16S rRNA and the groEL1 gene with and without antibiotics. Ofloxacin, moxifloxacin, azithromycin and doxycycline were tested against the serovar D and L2 reference strains and a derivative mutant resistant to fluoroquinolones, L2-OFXR, obtained by in vitro selection. Using DNA quantification, the antibiotic MIC was calculated when the number of DNA copies was equal to that of the chlamydial inoculum at time zero. This method allowed the easy determination of MICs by DNA quantification of the four selected genes and gave similar results to those obtained by immunofluorescence staining without biased interpretation. By using cDNA quantification, the lowest antibiotic concentration for which no RNA was transcribed corresponded to the minimum bactericidal concentration. C. trachomatis still transcribed the16S rRNA and groEL1 genes, even at concentrations well above the MIC, showing a bacteriostatic effect for all antibiotics tested. This method allows the study of antibiotic activity on growth and viability of C. trachomatis by DNA and RNA quantification at the same time without additional cell-culture passaging.
Journal of Microbiological Methods | 2009
Sophie Raherison; M. Clerc; Sabine Trombert; Sylvie Cado; F Normandin; C. Bébéar; Bertille de Barbeyrac
We developed a real-time High Resolution Melting PCR to identify the new Swedish variant of Chlamydia trachomatis ncCT. Of 1191 urogenital specimens C. trachomatis-positive by an omp1 real-time PCR, collected in France in 2007-2008, 1128 gave an interpretable profile corresponding to the wild-type strain; no nvCT was found. This test can be used on selected C. trachomatis-positive samples to monitor the nvCT spread.
Journal of Clinical Microbiology | 2009
Sophie Raherison; Olivia Peuchant; M. Clerc; Chloé Le Roy; C. Bébéar; Bertille de Barbeyrac; F Normandin; Isabelle Le Hen
We read with extreme interest the article by Moncada et al. ([2][1]) about the use of self-collected glans and rectal swabs for the detection of Chlamydia trachomatis in symptomatic and asymptomatic men who have sex with men (MSM). Indeed, our data complete and confirm those of Moncada et al., as we
Eurosurveillance | 2007
B. de Barbeyrac; Sophie Raherison; S Cado; F Normandin; M. Clerc; V Clairet; V Goulet; C. Bébéar
Clinical Microbiology and Infection | 2007
B. de Barbeyrac; Pablo Goldschmidt; S. Malembic; Sophie Raherison; M. Clerc; Bahram Bodaghi; C. Bébéar; Christine Chaumeil
Revue Francophone Des Laboratoires | 2007
Bertille de Barbeyrac; M. Clerc; Sophie Raherison; Cécile Bébéar; C. Bébéar
Archives of Disease in Childhood | 2010
Véronique Goulet; Bertille de Barbeyrac; Sophie Raherison; M. Prudhomme; Caroline Semaille; Josiane Warszawski
Bulletin Épidémiologique Hebdomadaire | 2009
T. Girard; S. Mercier; V. Viallon; H. Poupet; Sophie Raherison; C. Bébéar; A. Marchal; E. Bloch; D. Vernant; B. de Barbeyrac